Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page adds recruitment status information and new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) while standardizing the Intervention/Treatment label and updating the revision tag to v3.6.0.
    Difference
    0.5%
    Check dated 2026-06-15T08:31:39.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer now shows Revision: v3.5.5, replacing v3.5.4, indicating a small platform update that does not change the study details displayed on the page.
    Difference
    0.1%
    Check dated 2026-06-08T04:29:20.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The revision tag on the page updated from v3.5.3 to v3.5.4, indicating a minor system update that does not modify study details or results displayed.
    Difference
    0.1%
    Check dated 2026-05-18T03:27:02.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page’s platform/site revision label was updated from **v3.5.2** to **v3.5.3**, reflecting a behind-the-scenes release rather than a change to the clinical trial record.
    Difference
    0.1%
    Check dated 2026-04-26T15:20:16.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Added revision: v3.5.2; removed revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-19T13:30:37.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.3 to v3.5.0 on the page.
    Difference
    0.1%
    Check dated 2026-03-21T16:55:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.